Download PDF
Nuklearmedizin 2017; 56(01): 14-22
DOI: 10.3413/Nukmed-0846-16-09
Original article
Schattauer GmbH

Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma

Der diagnostische Nutzen des 68Ga-PSMA-PET vor einer 223Ra-Dichlorid-Therapie bei Patienten mit metastasiertem Prostatakarzinom
Axel Bräuer
1   Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
,
Kambiz Rahbar
1   Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
,
Julia Konnert
1   Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
,
Martin Bögemann
2   Department of Urology, University Hospital Münster, Münster, Germany
,
Lars Stegger
1   Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
› Author Affiliations
Further Information

Publication History

received: 01 September 2016

accepted in revised form: 13 January 2016

Publication Date:
02 January 2018 (online)

    Permissions and Reprints

Summary

Purpose: Medical imaging plays an important role in selecting patients with metastatic castration-resistant prostate cancer for 223Ra- dichloride therapy of bone metastases. The purpose of this study was to investigate whether 68Ga-PSMA-PET has incremental value over conventional imaging for selecting patients suitable for 223Ra-dichloride therapy. Methods: In 27 consecutive patients referred for 223Ra-dichloride therapy additional 68Ga-PSMA-PET/CT was performed and tracer distribution was evaluated systematically with respect to the detection of visceral metastases and bone metastases with inadequate uptake on bone scintigraphy. Results: In 4 patients (15 %) 68Ga- PSMA-PET revealed previously unknown visceral metastases (3 liver, 1 adrenal gland), which changed the therapeutic decision in 2 cases. PET revealed more extended tumour involvement in the bone compared to bone scintigraphy in 9 patients (33 %). In 3 of these, the mismatch was extensive enough to question suitability for 223Ra-dichloride therapy. Conclusions: Additional 68Ga-PSMA-PET as a gatekeeper between conventional staging and 223Ra-dichloride therapy can provide valuable additional information with regard to visceral metastases and tumour manifestations without adequate bone mineral turnover. It may lead to a change in therapeutic management in a significant number of patients and should therefore be considered in future clinical trials.

Zusammenfassung

Ziel: Die Bildgebung spielt eine wichtige Rolle für die Auswahl derjenigen Patienten mit einem metastasierten, kastrastionsrefraktärem Prostatakarzinom, die sich für eine 223Ra-Di- chlorid-Therapie von Knochenmetastasen eignen. Das Ziel dieser Studie war zu untersuchen, ob eine zusätzliche 68Ga-PSMA-PET ei nen inkrementellen Nutzen gegenüber der konventionellen Bildgebung für die Auswahl geeigneter Patienten für diese Therapie auf- weist.Methoden: Bei 27 konsekutiv für eine 223Ra-Dichlorid-Therapie vorgestellten Patienten wurde eine zusätzliche 68Ga-PSMA- PET/CT durchgeführt. Die Tracerverteilung wurde systematisch ausgewertet in Hinblick auf die Detektion von viszeralen Metastasen und auf ossäre Metastasen ohne adäquate Speicherung in der Skelettszintigraphie. Ergebnisse: Zusätzliche viszerale Metastasen wurden bei 4 Patienten (15%) mittels 68Ga- PSMA-PET detektiert (3 Leber, 1 Nebenniere), wobei das therapeutische Vorgehen bei 2 der 4 Patienten geändert wurde. Mit der PET wurde eine ausgedehntere Knochenmetastasierung im Vergleich zur Skelettszintigraphie bei 9 Patienten (33%) nachgewiesen. Bei dreien dieser Patienten war der „Mismatch” ausgedehnt genug, um die Durchführung der 223Ra-Dichlorid-Therapie in Frage zu stellen. Schlussfolgerung: Die zusätzliche 68Ga- PSMA-PET als Torwächter zwischen konventioneller Bildgebung und der 223Ra-Dichlorid- Therapie kann wichtige zusätzliche Informationen liefern über das Vorliegen von viszeralen Metastasen und von Tumormanifestationen ohne adäquaten Knochenstoffwechsel. Dieses kann bei einer signifikanten Zahl von Patienten zu einer Änderung des therapeutischen Managements führen und sollte für zukünftige klinische Studien berücksichtigt werden.

Keywords

prostate cancer - bone metastases - bone scintigraphy - 68Ga-PSMA-PET - 223Ra-dichloride - Xofigo®

Schlüsselwörter

Prostatakarzinom - Knochenmetastasen - Skelett szintigraphie - 68Ga-PSMA-PET - 223Ra-Dichlo rid - Xofigo®
 

  • References

  • 1 Afshar-Oromieh A, Babich JW, Kratochwil C. et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med 2016; 57: 79S-89S.
    CrossrefGoogle Scholar
  • 2 Afshar-Oromieh A, Haberkorn U, Eder M. et al. (68Ga)Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39: 1085-1086.
    CrossrefGoogle Scholar
  • 3 Ahmadzadehfar H, Azgomi K, Hauser S. et al. 68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept. J Nucl Med. 2016 DOI: jnumed.116.178533 Epub ahead of print
    Google Scholar
  • 4 Ahmadzadehfar H, Essler M, Schäfers M, Rahbar K. Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use. Nucl Med Biol 2016; 43 (12) 835.
    CrossrefGoogle Scholar
  • 5 Bier G, Hoffmann V, Kloth C. et al. CT imaging of bone and bone marrow infiltration in malignant melanoma-Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. Eur J Radiol 2016; 85: 732-738.
    CrossrefGoogle Scholar
  • 6 Bode A, Rahbar K, Konnert J. et al. Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy. Clin Nucl Med 2016; 41 (12) 951-952.
    CrossrefGoogle Scholar
  • 7 Budd RS, Hodgson GS, Hare WS. The relation of radionuclide uptake by bone to the rate of calcium mineralization. II:. Patient studies using 99Tcm-MDP Br J Radiol 1989; 62: 318-320.
    Google Scholar
  • 8 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674.
    CrossrefGoogle Scholar
  • 9 Fendler WP, Kratochwil C, Ahmadzadehfar H. et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin 2016; 55 (03) 123-128.
    Article in Thieme ConnectGoogle Scholar
  • 10 Giovanella L, Castellani M, Suriano S. et al. Multifield-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. Tumori 2011; 97: 629-633.
    Google Scholar
  • 11 Hawkins T, Halewood MM. Technical note: identifying the prostate cancer ,superscan by quantitative skeletal scintigraphy. Nucl Med Commun 2008; 29: 654-659.
    CrossrefGoogle Scholar
  • 12 itG. Ga-68 Radiolabeling KIT, Operating Manual, Version 1.0, Status 01/2014, itG, Garching, Germany 2014
  • 13 Lantto T, Vorne M, Mokka R, Vahatalo S. 99Tcm-MDP and 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison. Acta Radiol 1987; 28: 631-633.
    CrossrefGoogle Scholar
  • 14 O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol 2015; 7: 202-211.
    CrossrefGoogle Scholar
  • 15 Parker C, Nilsson S, Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (03) 213-223.
    CrossrefGoogle Scholar
  • 16 Pfister D, Porres D, Heidenreich A. et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging 2016; 43: 1410-1417.
    CrossrefGoogle Scholar
  • 17 Rahbar K, Ahmadzadehfar H, Kratochwil C. et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2016 DOI: jnumed.116.183194 Epub ahead of print
    Google Scholar
  • 18 Rahbar K, Bode A, Weckesser M. et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med 2016; 41: 522-528.
    CrossrefGoogle Scholar
  • 19 Rahbar K, Schmidt M, Heinzel A. et al. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J Nucl Med 2016; 57 (09) 1334-1338.
    CrossrefGoogle Scholar
  • 20 Rahbar K, Weckesser M, Huss S. et al. Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer. J Nucl Med 2016; 57: 563-567.
    CrossrefGoogle Scholar
  • 21 Rohren EM, Etchebehere EC, Araujo JC. et al. Determination of skeletal tumor burden on 18F-Fluoride PET/CT. J Nucl Med 2015; 56: 1507-1512.
    CrossrefGoogle Scholar
  • 22 Sartor O, Coleman R, Nilsson S. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15: 738-746.
    CrossrefGoogle Scholar
  • 23 Torre LA, Bray F, Siegel RL. et al. Global cancer statistics 2012. CA Cancer J Clin 2015; 65: 87-108.
    CrossrefGoogle Scholar
  • 24 Wakabayashi H, Nakajima K, Mizokami A. et al. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med 2013; 27: 802-807.
    CrossrefGoogle Scholar